{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:06:03Z","timestamp":1794027963515,"version":"4.8.0"},"reference-count":88,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,29]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hereditary hemorrhagic telangiectasia (HHT; Osler-Weber-Rendu disease) affects 1 in 5000 persons, making it the second most common inherited bleeding disorder worldwide. Telangiectatic bleeding, primarily causing recurrent epistaxis and chronic gastrointestinal bleeding, is the most common and most important manifestation of this multisystem vascular disorder. HHT-associated bleeding results in substantial psychosocial morbidity and iron deficiency anemia that may be severe. Although there remain no regulatory agency\u2013approved therapies for HHT, multiple large studies, including randomized controlled trials, have demonstrated the safety and efficacy of antifibrinolytics for mild-to-moderate bleeding manifestations and systemic antiangiogenic drugs including pomalidomide and bevacizumab for moderate-to-severe bleeding. This has led to a recent paradigm shift away from repetitive temporizing procedural management toward effective systemic medical therapeutics to treat bleeding in HHT. In this article, 4 patient cases are used to illustrate the most common and most challenging presentations of HHT-associated bleeding that hematologists are likely to encounter in daily practice. Built on a framework of published data and supported by extensive clinical experience, guidance is given for modern evidence\u2013based approaches to antifibrinolytic therapy, antiangiogenic therapy, and iron deficiency anemia management across the HHT disease severity spectrum.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023021765","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T08:53:57Z","timestamp":1718182437000},"page":"940-954","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":34,"title":["How I treat bleeding in hereditary hemorrhagic telangiectasia"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-1383","authenticated-orcid":false,"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2024082915260744500_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"2024082915260744500_bib2","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1002\/ajh.24832","article-title":"Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia","volume":"92","author":"Kasthuri","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2024082915260744500_bib3","doi-asserted-by":"crossref","first-page":"104370","DOI":"10.1016\/j.ejmg.2021.104370","article-title":"The European rare disease network for HHT frameworks for management of hereditary haemorrhagic telangiectasia in general and speciality care","volume":"65","author":"Shovlin","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"12","key":"2024082915260744500_bib4","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.mayocp.2016.07.005","article-title":"Effect of center volume on outcomes in hospitalized patients with hereditary hemorrhagic telangiectasia","volume":"91","author":"Iyer","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2024082915260744500_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.thromres.2017.03.003","article-title":"Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross-sectional survey","volume":"153","author":"Chaturvedi","year":"2017","journal-title":"Thromb Res"},{"issue":"9","key":"2024082915260744500_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1288\/00005537-199109000-00008","article-title":"The natural history of epistaxis in hereditary hemorrhagic telangiectasia","volume":"101","author":"Aassar","year":"1991","journal-title":"Laryngoscope"},{"issue":"4","key":"2024082915260744500_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care","volume":"136","author":"Al-Samkari","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2024082915260744500_bib8","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.7326\/L21-0067","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"174","author":"Faughnan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"4935","key":"2024082915260744500_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"issue":"2","key":"2024082915260744500_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2024082915260744500_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000072411","article-title":"Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia","volume":"110","author":"Cirulli","year":"2003","journal-title":"Acta Haematol"},{"issue":"7","key":"2024082915260744500_bib12","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3026(21)00164-2","article-title":"Giving hereditary haemorrhagic telangiectasia the attention it deserves","volume":"8","author":"Al-Samkari","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"2024082915260744500_bib13","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/GIM.0b013e3182136d32","article-title":"Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis","volume":"13","author":"McDonald","year":"2011","journal-title":"Genet Med"},{"issue":"4","key":"2024082915260744500_bib14","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"issue":"5","key":"2024082915260744500_bib15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/lary.25669","article-title":"The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia","volume":"126","author":"Yin","year":"2016","journal-title":"Laryngoscope"},{"issue":"11","key":"2024082915260744500_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoto.2020.3040","article-title":"Development and validation of the nasal outcome score for epistaxis in hereditary hemorrhagic telangiectasia (NOSE HHT)","volume":"146","author":"Peterson","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"suppl 1","key":"2024082915260744500_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10456-023-09886-5","article-title":"Executive summary of the 14th HHT international scientific conference","volume":"26","author":"Ola","year":"2023","journal-title":"Angiogenesis"},{"issue":"suppl 1","key":"2024082915260744500_bib18","first-page":"1","article-title":"2022 14th HHT international scientific conference abstracts","volume":"26","year":"2023","journal-title":"Angiogenesis"},{"issue":"12","key":"2024082915260744500_bib19","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/bloodadvances.2023011961","article-title":"Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder of women","volume":"8","author":"Zhang","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 2","key":"2024082915260744500_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/ijgo.14951","article-title":"The importance of iron deficiency in pregnancy on fetal, neonatal, and infant neurodevelopmental outcomes","volume":"162","author":"Georgieff","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"issue":"8","key":"2024082915260744500_bib21","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1002\/rth2.12444","article-title":"A\u00a0hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"2024082915260744500_bib25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/thoraxjnl-2011-201076","article-title":"Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli\/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia","volume":"67","author":"Livesey","year":"2012","journal-title":"Thorax"},{"issue":"10","key":"2024082915260744500_bib26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/ajh.25925","article-title":"Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia","volume":"95","author":"Song","year":"2020","journal-title":"Am J Hematol"},{"issue":"3","key":"2024082915260744500_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3324\/haematol.2020.270496","article-title":"Recognition of thrombotic risk of thrombocytosis in iron deficiency","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2024082915260744500_bib28","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3324\/haematol.2019.245092","article-title":"Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats","volume":"106","author":"Jimenez","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"2024082915260744500_bib22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.22153","article-title":"Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia","volume":"86","author":"Auerbach","year":"2011","journal-title":"Am J Hematol"},{"issue":"3","key":"2024082915260744500_bib23","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1053\/ajkd.2003.50141","article-title":"Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or\u00a0=250 mg) administration","volume":"41","author":"Folkert","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2024082915260744500_bib24","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.25548","article-title":"Single total dose infusion of ferumoxytol (1020 mg in 30 minutes) is an improved method of administration of intravenous iron","volume":"94","author":"Karki","year":"2019","journal-title":"Am J Hematol"},{"issue":"9","key":"2024082915260744500_bib29","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.2016.11724","article-title":"Effect of topical intranasal therapy on\u00a0epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial","volume":"316","author":"Whitehead","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"2024082915260744500_bib30","first-page":"1507","article-title":"Trauma can induce telangiectases in hereditary hemorrhagic telangiectasia","volume":"9","author":"Geisthoff","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"6","key":"2024082915260744500_bib31","first-page":"1688","article-title":"Surgery or no surgery? exploring the dilemma of epistaxis management in patients with HHT","volume":"13","author":"Passali","year":"2024","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"2024082915260744500_bib32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jama.2016.11387","article-title":"Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: a randomized clinical trial","volume":"316","author":"Dupuis-Girod","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"2024082915260744500_bib33","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/hed.23655","article-title":"Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial","volume":"37","author":"Riss","year":"2015","journal-title":"Head Neck"},{"issue":"5","key":"2024082915260744500_bib34","first-page":"1262","article-title":"Efficacy and safety of a 0.1% tacrolimus nasal ointment as a treatment for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled, multicenter trial","volume":"9","author":"Dupuis-Girod","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"2024082915260744500_bib35","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2024082915260744500_bib36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff","year":"2014","journal-title":"Thromb Res"},{"issue":"1","key":"2024082915260744500_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00277-014-2169-y","article-title":"The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey","volume":"94","author":"Zaffar","year":"2015","journal-title":"Ann Hematol"},{"issue":"1","key":"2024082915260744500_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-020-01453-1","article-title":"Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding","volume":"15","author":"Beckman","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"23","key":"2024082915260744500_bib39","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/CIRCULATIONAHA.117.033062","article-title":"Decreased expression of vascular endothelial growth factor receptor 1 contributes to the pathogenesis of hereditary hemorrhagic telangiectasia type 2","volume":"138","author":"Thalgott","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"2024082915260744500_bib40","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10456-014-9436-3","article-title":"VEGF neutralization can prevent and normalize arteriovenous malformations in an animal model for hereditary hemorrhagic telangiectasia 2","volume":"17","author":"Han","year":"2014","journal-title":"Angiogenesis"},{"issue":"2","key":"2024082915260744500_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2024082915260744500_bib42","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s13023-019-1239-6","article-title":"Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers","volume":"14","author":"Al-Samkari","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2024082915260744500_bib43","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jama.2012.250","article-title":"Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output","volume":"307","author":"Dupuis-Girod","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"2024082915260744500_bib44","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jhep.2013.02.006","article-title":"Improvement of ischemic cholangiopathy in three patients with hereditary hemorrhagic telangiectasia following treatment with bevacizumab","volume":"59","author":"Vlachou","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"suppl 2","key":"2024082915260744500_bib45","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1182\/blood-2023-191983","article-title":"PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia demonstrates that pomalidomide reduces epistaxis and improves quality of life [abstract]","volume":"142","author":"Al-Samkari","year":"2023","journal-title":"Blood"},{"issue":"8","key":"2024082915260744500_bib46","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2024082915260744500_bib58","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol"},{"issue":"4","key":"2024082915260744500_bib59","doi-asserted-by":"crossref","first-page":"340","DOI":"10.4193\/Rhino14.289","article-title":"Follow-up of thalidomide treatment in patients with hereditary haemorrhagic telangiectasia","volume":"53","author":"Hosman","year":"2015","journal-title":"Rhinology"},{"issue":"1","key":"2024082915260744500_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4274\/tjh.galenos.2018.2018.0190","article-title":"Thalidomide for the management of bleeding episodes in patients with hereditary hemorrhagic telangiectasia: effects on epistaxis severity score and quality of life","volume":"36","author":"Baysal","year":"2019","journal-title":"Turk J Haematol"},{"issue":"2","key":"2024082915260744500_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for epistaxis in patients with hereditary hemorrhagic telangiectasia: a preliminary study","volume":"157","author":"Fang","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"18","key":"2024082915260744500_bib77","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2303706","article-title":"Thalidomide for recurrent bleeding due to small-intestinal angiodysplasia","volume":"389","author":"Chen","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024082915260744500_bib78","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/archderm.1984.01650470072016","article-title":"Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures","volume":"120","author":"Aronson","year":"1984","journal-title":"Arch Dermatol"},{"issue":"11","key":"2024082915260744500_bib79","first-page":"629","article-title":"[Thalidomide induced peripheral neuropathy in multiple myeloma patients]","volume":"72","author":"Banach","year":"2015","journal-title":"Przegl Lek"},{"issue":"8","key":"2024082915260744500_bib80","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15354","article-title":"Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy","volume":"19","author":"Watson","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024082915260744500_bib47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1572-0241.2003.07185.x","article-title":"Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia","volume":"98","author":"Longacre","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2024082915260744500_bib48","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2024082915260744500_bib49","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10753-020-01378-8","article-title":"Thalidomide inhibits angiogenesis via downregulation of VEGF and angiopoietin-2 in Crohn\u2019s disease","volume":"44","author":"Wang","year":"2021","journal-title":"Inflammation"},{"issue":"4","key":"2024082915260744500_bib50","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat Med"},{"issue":"22","key":"2024082915260744500_bib51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V128.22.210.210","article-title":"Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a phase I study [abstract]","volume":"128","author":"Samour","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2024082915260744500_bib52","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial","volume":"294","author":"Dupuis-Girod","year":"2023","journal-title":"J\u00a0Intern Med"},{"issue":"8","key":"2024082915260744500_bib53","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.mayocp.2020.03.001","article-title":"Intravenous bevacizumab in hereditary hemorrhagic telangiectasia-related bleeding and high-output cardiac failure: significant inter-individual variability in the need for maintenance therapy","volume":"95","author":"Albitar","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2024082915260744500_bib54","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/hae.14034","article-title":"An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"26","author":"Al-Samkari","year":"2020","journal-title":"Haemophilia"},{"issue":"2","key":"2024082915260744500_bib55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Al-Samkari","year":"2019","journal-title":"J\u00a0Intern Med"},{"issue":"1","key":"2024082915260744500_bib56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"issue":"1","key":"2024082915260744500_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"2024082915260744500_bib62","doi-asserted-by":"crossref","first-page":"1146080","DOI":"10.3389\/fmed.2023.1146080","article-title":"Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"10","author":"Torres-Iglesias","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"2024082915260744500_bib63","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1002\/ajh.25563","article-title":"Octreotide for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: a prospective case series","volume":"94","author":"Kroon","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"2024082915260744500_bib64","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"2024082915260744500_bib65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/mol.110.067447","article-title":"Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells","volume":"79","author":"Albinana","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"18","key":"2024082915260744500_bib66","first-page":"5280","article-title":"Efficacy and safety of tacrolimus as treatment for bleeding caused by hereditary hemorrhagic telangiectasia: an open-label, pilot study","volume":"11","author":"Hessels","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"2","key":"2024082915260744500_bib67","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI127425","article-title":"Correcting smad1\/5\/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models","volume":"130","author":"Ruiz","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"7585","key":"2024082915260744500_bib68","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature16498","article-title":"FOXO1 couples metabolic activity and growth state in the vascular endothelium","volume":"529","author":"Wilhelm","year":"2016","journal-title":"Nature"},{"issue":"12","key":"2024082915260744500_bib69","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1017\/S0022215100081597","article-title":"The effect of oestrogen on the\u00a0nasal respiratory mucosa. An experimental histopathological and histochemical study","volume":"89","author":"Helmi","year":"1975","journal-title":"J\u00a0Laryngol Otol"},{"issue":"5","key":"2024082915260744500_bib70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.0954-6820.1981.tb11614.x","article-title":"Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial","volume":"209","author":"Vase","year":"1981","journal-title":"Acta Med Scand"},{"issue":"8695","key":"2024082915260744500_bib71","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0140-6736(90)91010-8","article-title":"Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone","volume":"335","author":"van Cutsem","year":"1990","journal-title":"Lancet"},{"issue":"2","key":"2024082915260744500_bib72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/lary.20065","article-title":"Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial","volume":"119","author":"Yaniv","year":"2009","journal-title":"Laryngoscope"},{"issue":"2","key":"2024082915260744500_bib73","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4193\/Rhino09.201","article-title":"Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial","volume":"49","author":"Yaniv","year":"2011","journal-title":"Rhinology"},{"issue":"4","key":"2024082915260744500_bib74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5603\/FHC.a2016.0022","article-title":"Doxycycline down-regulates matrix metalloproteinase expression and inhibits NF-kappaB signaling in LPS-induced PC3 cells","volume":"54","author":"Ogut","year":"2016","journal-title":"Folia Histochem Cytobiol"},{"issue":"5","key":"2024082915260744500_bib75","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/jth.15662","article-title":"North American study for the treatment of recurrent epistaxis with doxycycline: the NOSTRIL trial","volume":"20","author":"McWilliams","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2024082915260744500_bib76","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/s13023-022-02539-8","article-title":"Randomized, double-blind, placebo-controlled, crossover trial of oral doxycycline for epistaxis in hereditary hemorrhagic telangiectasia","volume":"17","author":"Thompson","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2024082915260744500_bib81","first-page":"1031","article-title":"Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism","volume":"98","author":"Shovlin","year":"2007","journal-title":"Thromb Haemost"},{"key":"2024082915260744500_bib82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fgene.2015.00101","article-title":"Circulatory contributors to the phenotype in hereditary hemorrhagic telangiectasia","volume":"6","author":"Shovlin","year":"2015","journal-title":"Front Genet"},{"issue":"1","key":"2024082915260744500_bib83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jtha.2022.09.003","article-title":"Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia","volume":"21","author":"Virk","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"2024082915260744500_bib84","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.thromres.2023.04.017","article-title":"Anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia: a scoping review","volume":"226","author":"Zhang","year":"2023","journal-title":"Thromb Res"},{"issue":"2","key":"2024082915260744500_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11239-023-02839-1","article-title":"Antithrombotic therapy for atrial fibrillation in hereditary hemorrhagic telangiectasia","volume":"56","author":"Virk","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"2024082915260744500_bib86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.thromres.2023.07.001","article-title":"Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: a large French cohort study (RETROPLACOTEL)","volume":"229","author":"Grobost","year":"2023","journal-title":"Thromb Res"},{"issue":"6","key":"2024082915260744500_bib87","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.otohns.2008.01.005","article-title":"Long-term complications of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia","volume":"138","author":"Levine","year":"2008","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"2024082915260744500_bib88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2500\/ajra.2012.26.3809","article-title":"The young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia","volume":"26","author":"Richer","year":"2012","journal-title":"Am J Rhinol Allergy"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/9\/940\/2239979\/blood_bld-2023-021765-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/9\/940\/2239979\/blood_bld-2023-021765-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T11:35:16Z","timestamp":1724931316000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/9\/940\/516493\/How-I-treat-bleeding-in-hereditary-hemorrhagic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":88,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,8,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023021765","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]}}}